These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37539467)

  • 1. Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors.
    Deng F; Sistonen J; Neuvonen M; Niemi M
    Basic Clin Pharmacol Toxicol; 2023 Oct; 133(4):428-436. PubMed ID: 37539467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Hepatic and Intestinal Efflux Transport of Statins.
    Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
    Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of
    Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
    Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
    Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR
    Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
    Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
    Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis.
    Luo J; Ou S; Wei H; Qin X; Jiang Q
    Front Oncol; 2022; 12():815265. PubMed ID: 35756600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
    Elsby R; Coghlan H; Edgerton J; Hodgson D; Outteridge S; Atkinson H
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01060. PubMed ID: 36811234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs.
    Deng F; Sjöstedt N; Santo M; Neuvonen M; Niemi M; Kidron H
    Eur J Pharm Sci; 2023 Feb; 181():106362. PubMed ID: 36529162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
    Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
    Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors.
    Guha M; Sobol Z; Martin M; Hemkens M; Sung T; Rubitski E; Spellman R; Finkelstein M; Khan N; Hu W
    Int J Toxicol; 2022 Dec; 41(6):442-454. PubMed ID: 35989659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
    Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
    J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
    Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
    Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
    Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
    Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials.
    Bao S; Yue Y; Hua Y; Zeng T; Yang Y; Yang F; Yan X; Sun C; Yang M; Fu Z; Huang X; Li J; Wu H; Li W; Zhao Y; Yin Y
    Ann Transl Med; 2021 Aug; 9(15):1229. PubMed ID: 34532366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
    Ringley JT; Moore DC; Patel J; Rose MS
    P T; 2018 Sep; 43(9):549-556. PubMed ID: 30186027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.